Leqembi (lecanemab) was approved by the FDA in 2023. It is an infusion drug that has been shown to reduce Alzheimer’s-related cognitive decline by up to 27%. 

A new analysis published in Artificial Intelligence in Medicine argues that education tools are failing to show clinicians how to make use of new technologies, calling into question the benefit of rapid adoption. 

Multiple lots of extended tip applicators from Integra LifeSciences could put patients at risk of serious infection, prompting the FDA to designate the recall as Class I.

A new report reveals that states are keeping databases on “imposter nurses” to slow what could be a growing trend of unlicensed individuals holding nursing positions at hospitals nationwide. 

OpenAI, the developer of ChatGPT, has made a couple of big hires as it prepares for a major expansion into healthcare.

Chatbots may be able to accurately explain MRI results to patients in ways that radiologists are not routinely available to do. 

The two said they’ve been negotiating terms for eight months. Sticking points include denied claims and coverage disputes, with both the insurer and health system pointing fingers.

Its alert pertains to over 26K carotid artery stents, used by interventional neuroradiologists, vascular surgeons and other docs to prevent strokes.